Psychosocial issues surrounding the general or restricted use of recombinant factor VIII: hemophilia clinic perspective.

Use of recombinant factor VIII in the management of hemophilia.

Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group.

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.

Factor VIII therapy for hemophilia A: current and future issues.

Long-lasting recombinant factor VIII proteins for hemophilia A.

Lower doses of factor VIII for hemophilia.

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.

Potential role of a new PEGylated recombinant factor VIII for hemophilia A.

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

The changing prognosis of classic hemophilia (factor VIII "deficiency").

A new recombinant factor VIII: from genetics to clinical use.

A new recombinant factor VIII: from genetics to clinical use.

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy.

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor.

Factor VIII Antigen, Activity, and Mutations in Hemophilia A.

Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group.

The manufacturing of the recombinant factor VIII, Kogenate.

Psychosocial issues in hemophilia before and after the HIV crisis: a review of current research.

Suggest Documents

Use of recombinant factor VIII in the management of hemophilia.

Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group.

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.

Factor VIII therapy for hemophilia A: current and future issues.

Long-lasting recombinant factor VIII proteins for hemophilia A.

Lower doses of factor VIII for hemophilia.

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.

Potential role of a new PEGylated recombinant factor VIII for hemophilia A.

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

The changing prognosis of classic hemophilia (factor VIII "deficiency").

A new recombinant factor VIII: from genetics to clinical use.

A new recombinant factor VIII: from genetics to clinical use.

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy.

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor.

Factor VIII Antigen, Activity, and Mutations in Hemophilia A.

Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group.

The manufacturing of the recombinant factor VIII, Kogenate.

Psychosocial issues in hemophilia before and after the HIV crisis: a review of current research.

Psychosocial issues surrounding the general or restricted use of recombinant factor VIII: hemophilia clinic perspective.

Recommend Documents

Follow Us